Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer.

ABSTRACT:

Background

Breast cancer (BC) is a prevalent disease that harms women's health, and in-depth investigations of the pathogenesis, treatment, and prevention of BC are the focus of many research programs. Chidamide (CHI) is a histone deacetylase suppressor that depresses histone deacetylase functions, thereby influencing cell growth through an epigenetic mechanism. However, CHI effects upon BC are largely unknown. Present research aimed to confirm the possibility of using CHI combined with chemotherapy drug doxorubicin (DOX) to prevent chemotherapeutic BC resistance in vivo and in vitro.

Methods

In this study, CCK8 (a plate colony formation assay) was applied to detect cell proliferation. Flow cytometry detection showed the apoptotic cell death of both T47D and MCF-7 cells. Nud

SUBMITTER: Li J 

PROVIDER: S-EPMC10111806 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature